On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the ?Company?) entered into a Transition and Separation Agreement (the ?Agreement?) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024. Dr. Wilbur's departure is not due to any disagreement with the Company?s management team, operations, financial statements, policies or procedures.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.59 USD | +2.57% | -1.25% | -50.70% |
Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.70% | 3.3B | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B | |
-5.02% | 1.64B | |
-8.80% | 1.53B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024